[1st clinical studies in therapy of shock with ornithine-8-vasopressin (POR-8)].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D001775:Blood Circulation / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D009952:Ornithine / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D012769:Shock / Q000188:drug therapy*; D012770:Shock, Cardiogenic / Q000188:drug therapy; D012771:Shock, Hemorrhagic / Q000188:drug therapy; D014667:Vasopressins / Q000494:pharmacology / Q000627:therapeutic use*
D014667:Vasopressins; D009952:Ornithine
Erste klinische Erfahrungen in der Schocktherapie mit Ornithin-8-Vasopressin (POR-8.